Literature DB >> 15741466

Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up.

Peter Milev1, Beng-Choon Ho, Stephan Arndt, Nancy C Andreasen.   

Abstract

OBJECTIVE: The relationship between cognition and outcome in people with schizophrenia has been established in studies that, for the most part, examined chronic patients and were cross-sectional in design. The purpose of this study was to analyze the relationships between neurocognitive variables assessed at illness onset and functional outcome in a longitudinal design. An additional area of interest was whether the severity of negative symptoms would predict outcome independently from neurocognitive variables or whether there would be an overlap in their predictive power.
METHOD: The authors administered a comprehensive cognitive battery and clinical assessments to 99 subjects who were in their first episode of illness and analyzed the relationship of cognition and symptom severity at intake with community outcome after an average follow-up period of 7 years.
RESULTS: Verbal memory, processing speed and attention, and the severity of negative symptoms at intake were related to subsequent outcome. Global psychosocial functioning was predicted by negative symptoms and attention. Verbal memory was the significant predictor of the degree of impairment in recreational activities. Impairment in relationships was predicted by negative symptoms and memory, whereas attention and negative symptoms were predictive of work performance. There was an overlap in the variance in outcome explained by cognitive variables and negative symptoms.
CONCLUSIONS: Verbal memory and processing speed and attention are potential targets for psychosocial interventions to improve outcome. Results from cross-sectional or chronic patient studies do not necessarily correspond to the findings of this prospective first-episode study in which cognition appears to explain less of the variance in outcome.

Entities:  

Mesh:

Year:  2005        PMID: 15741466     DOI: 10.1176/appi.ajp.162.3.495

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  214 in total

1.  Rasagiline in the Treatment of the Persistent Negative Symptoms of Schizophrenia.

Authors:  Robert W Buchanan; Elaine Weiner; Deanna L Kelly; James M Gold; William R Keller; James A Waltz; Robert P McMahon; David A Gorelick
Journal:  Schizophr Bull       Date:  2014-11-02       Impact factor: 9.306

2.  Processing speed and executive functions predict real-world everyday living skills in adolescents with early-onset schizophrenia.

Authors:  O Puig; R Penadés; I Baeza; V Sánchez-Gistau; E De la Serna; L Fonrodona; S Andrés-Perpiñá; M Bernardo; J Castro-Fornieles
Journal:  Eur Child Adolesc Psychiatry       Date:  2012-02-22       Impact factor: 4.785

3.  The prospective relationships among intrinsic motivation, neurocognition, and psychosocial functioning in schizophrenia.

Authors:  Eri Nakagami; Maanse Hoe; John S Brekke
Journal:  Schizophr Bull       Date:  2010-05-12       Impact factor: 9.306

4.  Resting quantitative cerebral blood flow in schizophrenia measured by pulsed arterial spin labeling perfusion MRI.

Authors:  Amy Pinkham; James Loughead; Kosha Ruparel; Wen-Chau Wu; Eve Overton; Raquel Gur; Ruben Gur
Journal:  Psychiatry Res       Date:  2011-08-09       Impact factor: 3.222

5.  Conceptualization and treatment of negative symptoms in schizophrenia.

Authors:  Sonali Sarkar; Kiley Hillner; Dawn I Velligan
Journal:  World J Psychiatry       Date:  2015-12-22

6.  Attention/processing speed prospectively predicts social impairment 18 years later in mood disorders.

Authors:  Casey Sarapas; Stewart A Shankman; Martin Harrow; Robert N Faull
Journal:  J Nerv Ment Dis       Date:  2013-09       Impact factor: 2.254

7.  Visual Cortical Alterations and their Association with Negative Symptoms in Antipsychotic-Naïve First Episode Psychosis.

Authors:  Iniya Adhan; Paulo Lizano; Deepthi Bannai; Olivia Lutz; Kiranpreet Dhaliwal; Victor Zeng; Jean Miewald; Debra Montrose; Matcheri Keshavan
Journal:  Psychiatry Res       Date:  2020-04-16       Impact factor: 3.222

8.  Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia.

Authors:  Beng-Choon Ho; Thomas H Wassink; Steven Ziebell; Nancy C Andreasen
Journal:  Schizophr Res       Date:  2011-03-21       Impact factor: 4.939

9.  Neurocognitive functioning in patients with first-episode schizophrenia : results of a prospective 5-year follow-up study.

Authors:  Margot Albus; Werner Hubmann; Fritz Mohr; Susanne Hecht; Petra Hinterberger-Weber; Nichi-Niels Seitz; Helmut Küchenhoff
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-10-09       Impact factor: 5.270

10.  Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later.

Authors:  Joseph Ventura; Kenneth L Subotnik; Michael J Gitlin; Denise Gretchen-Doorly; Arielle Ered; Kathleen F Villa; Gerhard S Hellemann; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2014-12-08       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.